MDWD Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 23:00):

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration...

Stats
Dzisiejszy wolumen	40 513.00
Średni wolumen	78 048.00
Kapitalizacja rynkowa	177.02M
EPS	$0 ( 2024-03-21 )
Następna data zysków	( $-0.400 ) 2024-06-04
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-24.87
ATR14	$0.0820 (0.44%)

Wolumen Korelacja

Długi: 0.01 (neutral)

Krótki: 0.77 (moderate)

Signal:(47.727) Neutral

Mediwound Ltd Korelacja

10 Najbardziej pozytywne korelacje
TBSAU	0.936
ENTF	0.935
TCOM	0.928
VPCB	0.926
FNVT	0.925
CCLP	0.925
LEGA	0.924
AGGR	0.924
FRONU	0.922
AFAR	0.921

10 Najbardziej negatywne korelacje
GPRO	-0.922
OLPX	-0.921
TLGT	-0.92
GOODM	-0.918
CNTG	-0.914
UDMY	-0.911
AGRX	-0.909
BHTG	-0.906
PTE	-0.905
PACB	-0.904

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Mediwound Ltd Korelacja - Waluta/Towar

-0.31
( neutral )

-0.41
( neutral )

0.00
( neutral )

-0.07
( neutral )

0.41
( neutral )

0.47
( neutral )

Mediwound Ltd Finanse

Annual	2023
Przychody:	$18.69M
Zysk brutto:	$2.95M (15.77 %)
EPS:	$-0.750

FY	2023
Przychody:	$18.69M
Zysk brutto:	$2.95M (15.77 %)
EPS:	$-0.750

FY	2022
Przychody:	$26.50M
Zysk brutto:	$13.17M (49.69 %)
EPS:	$-3.93

FY	2021
Przychody:	$23.76M
Zysk brutto:	$8.77M (36.91 %)
EPS:	$-0.0711

Financial Reports:

No articles found.

Mediwound Ltd

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.